Structural Insight into the Mode of Action of a Direct Inhibitor of Coregulator Binding to the Thyroid Hormone Receptor. by Estébanez Perpiñá, Eva et al.
Structural Insight into the Mode of Action of a
Direct Inhibitor of Coregulator Binding to the
Thyroid Hormone Receptor
Eva Este´banez-Perpin˜a´,* Leggy A. Arnold,* Natalia Jouravel,* Marie Togashi, Justin Blethrow,
Ellena Mar, Phuong Nguyen, Kevin J. Phillips, John D. Baxter, Paul Webb, R. Kiplin Guy, and
Robert J. Fletterick
Department of Biochemistry and Biophysics (E.E.-P., N.J., E.M., R.J.F.), University California San
Francisco, San Francisco, California 94158; Department of Chemical Biology and Therapeutics
(L.A.A., R.K.G.), St. Jude Children’s Research Hospital, Memphis, Tennessee 38105; and Diabetes
Center and Department of Medicine (M.T., P.N., K.J.P., J.D.B., P.W.) and Department of Cellular and
Molecular Pharmacology (J.B.), University California San Francisco, San Francisco, California 94143
The development of nuclear hormone receptor
antagonists that directly inhibit the association
of the receptor with its essential coactivators
would allow useful manipulation of nuclear hor-
mone receptor signaling. We previously identi-
fied 3-(dibutylamino)-1-(4-hexylphenyl)-propan-1-
one (DHPPA), an aromatic !-amino ketone that
inhibits coactivator recruitment to thyroid hor-
mone receptor ! (TR!), in a high-throughput
screen. Initial evidence suggested that the aro-
matic !-enone 1-(4-hexylphenyl)-prop-2-en-1-one
(HPPE), which alkylates a specific cysteine residue
on the TR! surface, is liberated from DHPPA. Nev-
ertheless, aspects of the mechanism and specific-
ity of action of DHPPA remained unclear. Here, we
report an x-ray structure of TR! with the inhibitor
HPPE at 2.3-Å resolution. Unreacted HPPE is lo-
cated at the interface that normally mediates bind-
ing between TR! and its coactivator. Several lines
of evidence, including experiments with TR! mu-
tants and mass spectroscopic analysis, showed
that HPPE specifically alkylates cysteine residue
298 of TR!, which is located near the activation
function-2 pocket. We propose that this covalent
adduct formation proceeds through a two-step
mechanism: 1) !-elimination to form HPPE; and 2)
a covalent bond slowly forms between HPPE and
TR!. DHPPA represents a novel class of potent
TR! antagonist, and its crystal structure suggests
new ways to design antagonists that target the
assembly of nuclear hormone receptor gene-reg-
ulatory complexes and block transcription. (Molec-
ular Endocrinology 21: 2919–2928, 2007)
THE NUCLEAR HORMONE receptor (NR) family oftranscription factors is a target for pharmaceutical
development, and many NR antagonists are in current
use (1, 2). For example, estrogen receptor (ER) antag-
onists such as tamoxifen and faslodex inhibit growth
and recurrence of estrogen-dependent breast cancer
(3). Likewise, androgen receptor (AR) antagonists such
as hydroxyflutamide and bicalutamide are used to
treat androgen-dependent prostate cancers (4, 5).
Other available NR inhibitors include spironolactone,
which reduces mortality after heart attack (6), and
RU486, which is used as emergency birth control (7).
New NR inhibitors would most likely be useful for
treating certain diseases. Thyroid hormone (TH) receptor
(TR) antagonists could provide rapid-acting therapies for
hyperthyroidism (excess TH production), particularly for
use during thyroid storm, a life-threatening thyrotoxic
crisis. Antagonists selective for the TR! isoform, which
regulates heart rate, could be used to treat cardiac ar-
rhythmias (8, 9).
NRs are composed of three modular domains (10, 11):
the C-terminal ligand-binding domain (LBD), the ligand-
dependent transactivation function (AF-2), and the N-
terminal transactivation function (AF-1) domain. Hor-
mone binds the LBD and activates AF-2, which, in turn,
recruits coactivators (12, 13). All NR antagonists that are
currently available for clinical use competitively inhibit
hormone binding (5). Most NR antagonists are believed
to work either by precluding formation of an active LBD
conformation or by inducing an aberrant LBD conforma-
tion that does not permit AF-2 activity. A number of
alternate mechanisms have been suggested, including
inhibition of NR via enhanced corepressor recruitment to
a surface that partially overlaps AF-2, increased NR turn-
over, blockade of NR dimer formation, and inhibition of
the AF-1 domain (13).
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The molecular basis for NR antagonism is well under-
stood (8, 9, 14). NR LBDs comprise a sandwich of three
distinct layers formed by 1–12 !-helices (H1–H12) and four
short "-strands with activating ligands enclosed in the hy-
drophobic core of the domain (15). Agonists enhance the
packing of the C-terminal helix (H12) over the lower part of
the LBD (H3 and H5), completing the AF-2 surface (15).
Many antagonists resemble cognate hormone but contain
bulky extensions that displace H12. Others occupy the
hormone-binding pocket but fail to form a hydrogen bond
network, which is required for H12 packing (8). This knowl-
edge has been already exploited to create new antagonists
for TRs and many other NRs (8).
However, despite these successes, new NR antago-
nists are still needed. Many ligand-dependent NRs can
influence transcription in the absence of hormone. For
example, ERs and AR acquire the capacity to activate
transcription in the presence of antagonists during pro-
gression of breast or prostate cancer (17, 18). Further-
more, many NRs are not ligand dependent. The LBD of
the orphan nuclear receptor 1 lacks a conventional hor-
mone-binding pocket, and ligands of the hepatocyte
nuclear factor-4! (14- to 18-chain fatty acids) bind tightly
and are better described as prosthetic groups (19). We
and others have suggested that directly blocking the
coregulator-binding site would afford antagonists that
have been referred to as surface-interacting drugs
(SIDs). SIDs inhibit key NR protein-protein interaction
surfaces and could block NR activity, irrespective of
hormone responsiveness of the target cell or the pres-
ence or absence of the ligand (20–22). Additionally, SIDs
that target unique regions of the NR surface should ex-
hibit better specificity than conventional antagonists,
which show troubling cross-reaction with hormone-
binding pockets of closely related NRs.
The NR AF-2 surface is an attractive target for candi-
date SIDs, because it is deeply articulated and has sig-
nificant hydrophobic character (15, 20, 23). Combined
x-ray structural analysis and scanning-surface mutagen-
esis approaches indicated that TR AF-2 is a small con-
cave surface and that only six hydrophobic residues
(V284, K288, I302, K306, L454, and E457) are crucial for
its function (24). This surface binds short coactivator
domains (NR boxes) that conform to the consensus NR-
interaction motif, leucine-x-x-leucine-leucine, and form
short !-helices with one face being predominantly hy-
drophobic (24, 25).
In previous work, we identified two molecules that
inhibit interactions between TR" and the steroid receptor
coactivator 2 (SRC2) with IC50 values of approximately 2
#M (21). We also showed that one of these compounds,
3-(dibutylamino)-1-(4-hexylphenyl)-propan-1-one (DH-
PPA, Fig. 1) is more than 10-fold selective for TR" over
the closely related TR! isoform. DHPPA1 does not dis-
place T3 from TR in vitro but inhibits TR" activity in vivo
when the receptor is saturated with TH. It appears to
have no gross effects upon protein structure or stability.
Other groups have reported compounds that act on the
ER (26–29).
Several lines of evidence suggested that DHPPA
was a prodrug, the active species of which, "-enone
1-(4-hexylphenyl)-prop-2-en-1-one (HPPE) acted irre-
versibly. DHPPA is a member of a class of compounds
called Mannich bases, which undergo slow "-elimina-
tion in solution at physiological pH to form !,"-unsat-
urated ketones that alkylate nearby electron-rich
groups, with a strong preference for nucleophilic sulfur
such as that of cysteine side chains (30). We found
that HPPE potently inhibits TR" AF-2 activity in bio-
chemical and cell culture models. Moreover, DHPPA
inhibition of TR" interactions with coactivators is time
dependent and requires stoichiometric amounts of
compound, hallmarks of irreversible inhibition. Finally,
incubation of TR" LBD with DHPPA increases TR"
molecular weight in a manner consistent with adduct
formation between TR" and a single HPPE molecule.
We also noted that several cysteine residues are ex-
posed on the TR" surface, including three close to
AF-2 (Cys309, Cys298, and Cys294). Mutation of
Cys309 weakens the actions of DHPPA, although we
did not confirm a covalent bond between this residue
and HPPE.
In this study, we investigate the mechanism of DH-
PPA action by using x-ray crystallography and di-
rected mutagenesis of the TR" coactivator-binding
surface. The results suggest that DHPPA inhibits TR"
action by rapidly liberating the reactive !,"-unsatur-
ated ketone HPPE at the TR" AF-2 surface and that
this intermediate, in turn, reacts in a slower step with
the nearby Cys298 residue to occlude AF-2. This
mechanism exploits the intrinsic activity of the SRC-
binding site to generate intermediates that modify nu-
cleophilic groups that are accessible and activated by
their environment. This is a mechanism of action rem-
iniscent of enzyme-suicide inhibition. These charac-
1 The compounds DHPPA and HPPE were named gener-
ically L1 and L3, respectively (21). Their official names are
SJ-000000001 and SJ-000000002, respectively. The com-
pound HPPA is officially named SJ-000000055.
Fig. 1. Structures of Inhibitors of the Interaction of TR" LBD
and SRC2
A, The "-amino-ketone DHPPA [3-(dibutylamino)-1-(4-
hexylphenyl)propan-1-one] was used in the soaking experi-
ments. B, The !,"-unsaturated ketone HPPE [1-(4-hexylphe-
nyl)prop-en-1-one] was the compound seen in the structure.
C, The inactive compound HPPA [1-(4-hexylphenyl)propan-
1-one] was used as the control.
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teristics may be a useful paradigm for development of
new selective NR antagonists.
RESULTS
Reaction of the TR! LBD with DHPPA
To understand the mechanism of reaction between
DHPPA and TR", we carried out several studies to
determine the reactivity of individual LBD-exposed
cysteine residues and the degree to which unbound
HPPE is generated. If HPPE is generated locally and
reacts with an immediately adjacent sulfhydryl, then
DHPPA activity should be resistant to exogenous thi-
ols in the buffer, and the majority of the conjugated
HPPE should be directed to the TR". Indeed, when
coactivator-binding experiments were carried out in
the presence of increasing amounts of "-mercapto-
ethanol (BME, 10 nM to 10 mM), no external product
resulting from the conjugation of HPPE with BME was
detected by mass spectrometry (see supplemental
data Fig. 1 published on The Endocrine Society’s
Journals Online web site at http://mend.endojournal-
s.org). Additionally, the DHPPA inhibitor remained fully
active with no shifts in potency or efficacy until the
concentration of BME exceeded 10 mM (a "20,000-
fold excess relative to protein). These findings suggest
that the HPPE is generated within the binding site and
remains bound to that site until it reacts with one of the
local cysteines.
We also assessed the sensitivity of TR" to nonspe-
cific alkylators that attack surface-exposed sulfhydryls
to determine whether a particularly reactive cysteine
residue was present or if the protein was particularly
sensitive to electrophiles. To assess these issues, we
conducted coactivator-binding experiments in the
presence of increasing concentrations (10 nM to 10
mM) of the sulfhydryl-reactive reagents iodoacetamide
and N-ethylmaleimide (see supplemental data Figs. 2
and 3). Neither of these reagents had strong influence
on the behavior of TR". In fact, no difference in coac-
tivator binding was detected for either reagent until its
concentration exceeded 100 #M (iodoacetamide) and
1 mM (N-ethylmaleimide), which, relative to the
amounts of protein present, were about 1,000-fold
and 10,000-fold excess, respectively. The potency of
iodoacetamide was also approximately 100-fold lower
than that of DHPPA or HPPE, and the potency of
N-ethylmaleimide was 1000-fold lower. These findings
imply that some characteristic of HPPE provides a
specific alkylation event that blocks function.
In addition to these experiments, we reexamined
previously published high-resolution TR crystal struc-
tures resulting from crystals that had been soaked with
or grown in the presence of such vast excesses of
nonspecific alkylators [(Protein Data Bank (PDB) iden-
tification nos. 2H6WX, 2H77A, 2H79A, and others).
Surface-exposed cysteine residues in these structures
were found to have reacted with buffer components,
and there was an even distribution of alkylation events
among exposed cysteines of Cys294, Cys298,
Cys388, and Cys434 and their TR! equivalents. To-
gether, these findings imply that the inactivation of
TR" by DHPPA is the result of a specific, targeted
alkylation event that results from interaction of the
particular electrophile with the protein surface, prob-
ably through positioning of the electrophilic pharma-
cophore element and not due to a particularly reactive
cysteine residue.
Structure of the TR! LBD-Ketone Complex
To understand how DHPPA inhibits coactivator bind-
ing to TR", we set out to image the compound at the
TR surface. Attempts to cocrystallize TR" LBD in com-
plex with the TH Triac (3,3!,5-triiodothyroacetic acid)
and DHPPA were not successful. We therefore first
obtained crystals of a TR" mutant (TR" D355R) in
complex with Triac and then soaked crystals for vary-
ing times with DHPPA solutions, as described in Ma-
terials and Methods. This TR" mutant formed stable
dimers in solution but otherwise displayed normal
transcriptional activity (Ref. 31; and Jouravel, N., M.
Togashi, E. Sablin, J. D. Baxter, P. Webb, and R. J.
Fletterick, manuscript in preparation) and was chosen
here because it forms long-lived crystals that are rel-
atively stable (data not shown).
Long-term treatment of preformed TR" D355R:Triac
crystals with DHPPA solution resulted in significant
dimensional changes in the lattice. Crystals failed to
diffract beyond 10 Å when soaked for 2 h. Crystals that
were soaked with DHPPA for as long as 1 h diffracted
to 2.3 Å, thereby permitting structural analysis and
assignment of the compound to the TR surface. The
secondary and tertiary structures of the TR" D355R
mutant were identical to those of wild-type TRs. Two
molecules of TR" D355R formed a dimer (monomer A
and B) with a root mean square between monomers of
0.47 Å; Triac was buried inside the ligand-binding
pocket. Given extensive similarities between this and
previously elucidated TR structures (32–34), the de-
tails of TR" LBD organization will not be further
described.
We detected a single compound at the TR AF-2
surface. Consistent with our predicted mechanism,
this was HPPE, the product of DHPPA "-elimination,
and not the parental DHPPA compound that was used
in the soaks (Fig. 1). HPPE has three pharmacophore
components: a hydrophobic alkyl chain, a hydropho-
bic benzyl ring, and a hydrophilic unsaturated ketone
substituent that make up the reactive site. All of these
features were clearly visible. No evidence indicated
the presence of the amine group that is characteristic
of DHPPA. We were not able to detect DHPPA or
HPPE binding to any other region of the TR LBD sur-
face. Our analysis of the relative electron densities of
the compound and receptor suggested that there was
1:1 stoichiometry.
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As observed in the crystal structure, HPPE was unre-
acted with TR but positioned close to several cysteine
residues (Fig. 2). As described above, TR" AF-2 is a small
concave surface that contains the following six hydropho-
bic residues that are essential for coactivator recruitment:
V284, K288, I302, K306, L454, and E457. The HPPE alkyl
chains bind to a hydrophobic patch formed by L454 and
V284; the aromatic ring binds to the concave AF-2 surface,
making contacts with L454, V284, and I302. The ketone
carbonyl oxygen engages in awater-mediated electrostatic
interaction with the K306 amino group, although the dis-
tance between these residues (5.7 Å) and that from E457
("5.5 Å) eliminates the possibility of a true hydrogen bond
forming. Overall, these interactions guide the reactive hy-
drophilic portion of the HPPE molecule close to four cys-
teine residues. The unsaturated enone part of the molecule
lies about 6.5 Å from Cys309, which is located in the base
of the AF-2 cleft. The side chain of Cys308 is buried within
the core of the domain with side chain atoms and main
chain atoms forming a separation wall between it and the
enone. The reactive group of HPPE also lies within 10 Å of
Cys298 and Cys294, which are represented on the upper
right and right corners of the AF-2 site.
Together, our results suggest that HPPE is liberated
from DHPPA in the TR" crystal and stably binds within
the AF-2 cleft. Previous chemical analyses showed
that HPPE binds irreversibly to the TR" LBD with
strong time dependency (21). The fact that our crystal
contains an unreacted HPPE molecule suggests that
the structure corresponds to an intermediate stage of
this two-step reaction.
Identification of Covalent Attachment Sites of
HPPE on TR! LBD
To understand how HPPE inhibits TR AF-2 activity, we
set out to identify the most likely target(s) of HPPE
modification using mass spectrometry of treated pro-
tein. Trypsin-digested control and HPPE-treated pro-
tein samples were used to define the precise site(s) on
TR that was modified by treatment with HPPE. We
analyzed the resulting peptides by nanoscale liquid
chromatography coupled online to a tandem mass
spectrometer. Fragmentation spectra were acquired
automatically and interpreted manually and via the use
of the MASCOT protein database-searching program
(Matrix Science, Boston, MA). Alkylation by HPPE was
observed in a peptide spanning residues 289–306
(KLPMFCELPCEDQIILLK) (Fig. 3). Fragmentation
spectra were obtained for both the [M#2H]2# and
[M#3H]3# precursor ion forms, and in both cases,
Cys298 was conclusively shown to be the site of mod-
ification. Comparison of the integrated ion intensities
from the normal and modified forms of this peptide
suggested stoichiometric modification at this site;
however, possible differences in the relative ability of
the two species to ionize precluded a quantitative
appraisal of the extent of modification.
Despite observing peaks corresponding to fragment
peptides spanning most of the HPPE-binding site, we
did not observe peptides that included Cys308 and/or
Cys309 in either the control or experimental samples.
Thus, although Cys298 is readily modified by HPPE,
we cannot rule out some degree of reaction with
Cys309 or its neighbor. Nevertheless, mass spectrom-
etry did confirm that Cys294 was unreacted.
Two other sites were modified at very low stoichi-
ometry ($0.1), Lys211 and Cys388. Lys211 is a highly
accessible residue located at the beginning of the
N-terminal fragment of the LBD TR" structure, before
helix 1. It is fully solvent accessible, and it is not
located in any secondary structure element. Cys388 is
also surface exposed and located at the C terminus of
Fig. 2. Close-up of HPPE Bound into the TR" LBD AF-2 Pocket
A, Solid representation of TR" LBD is depicted. The negatively charged residues are red, the positively charged residues are
blue, the hydrophobic residues are lilac, and the cysteine residues are yellow. B, The TR" AF-2 surface and the compound HPPE
are shown as a gray stick model placed inside the AF-2 pocket. The distance between HPPE and K306 was 5.7 Å (white dotted
line); that to E457, 5.7 Å (green dotted line); that to the unsaturated carbon and C309, 6.5 Å (black dotted line); and that to C298,
7.7 Å (yellow dotted line). C, The TR" AF-2 surface and the compound HPPE (shown as a gray stick model). A pale gray mesh
is included to show the volume of the AF-2 pocket that the compound occupies. The figure was generated using PyMOL (16).
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helix 9, on the opposite side of the receptor from AF-2.
Together, our results suggest that Cys298, which is
adjacent to the AF-2 surface, is the major target for
HPPE modification.
Mutation of Cys 298 Creates a TR that Binds
Coactivators but Is Resistant to DHPPA
To assess the role of Cys298 in DHPPA inhibition of TR
activity, we determined the effect of mutation of
Cys298 on cofactor binding and DHPPA reactivity.
Significant amounts of T3-liganded wild-type TR"
were retained on an affinity column in which the NR-
interaction domain of the coactivator SRC2 was at-
tached to the solid support (Fig. 4). TR" alone (i.e.
uncoupled from its ligand) did not bind to the column
(data not shown). Incubation with increasing amounts
of DHPPA or HPPE inhibited TR" binding to its coac-
tivator SRC2 in a dose-dependent manner, whereas
an unreactive control compound 1-(4-hexylphenyl-
)propan-1-one (HPPA) did not. In parallel, a TR" mu-
tant in which serine was substituted for Cys298
(C298S) bound strongly to the column, confirming that
this residue is not needed for TR" to bind the coacti-
vator and is insensitive to DHPPA and HPPE action.
Thus, Cys298 is not required for cofactor binding but
is necessary for DHPPA activity.
To explore the roles of the cysteine residues located
near the AF-2 pocket in DHPPA action, we examined
the effects of mutations that targeted key residues
surrounding the AF-2 surface but permitted some co-
factor binding. Cys298 mutations C298S and C298R
suppressed the ability of DHPPA to inhibit cofactor
binding, whereas a mutation at Cys294 (C294K) did
not (Fig. 5, upper panel). A mutation of Cys309
(C309A) that permitted coactivator binding also failed
to reverse the ability of DHPPA to inhibit SRC2 binding
(Fig. 5, lower panel).
Both the elimination of DHPPA to form HPPE and
the reaction of DHPPA with nucleophilic groups at the
TR surface should be affected by mutations that alter
the electrostatic environment at the reaction site. Not
surprisingly, mutations in charged residues that sur-
round the AF-2 cleft modestly reduced the efficacy of
DHPPA. Removal of the positive charge at lysine res-
idue 306 reduced the efficacy of DHPPA (Fig. 5, lower
panel), even though we did not detect modification of
this residue in mass spectroscopic analysis. In con-
trast, removal of the charge at glutamate residue 457
or lysine 288 on H12 had no effect (Fig. 5, lower panel).
Fig. 4. Mutation at Cys298 Abolishes the Sensitivity of TR"
to DHPPA Inhibition
SDS-PAGE gel showing quantities of in vitro-translated T3-
liganded TR" or the mutant TR" C298S retained in pull-down
assays using bacterially expressed GST-SRC2 (amino acids
563-1121) at 3 #g per assay. Binding is shown in assays per-
formed with increasing concentrations (micromolar) of DHPPA,
HPPE, or the control inactive compound HPPA.
Fig. 3. Mass Spectrometric Identification of HPPE Modification of Cys298
The fragmentation spectrum collected for a peptide spanning K289 to K306 and containing a covalent HPPE adduct at C298
is shown. The peptide ([M#H]#: 2349.26) was observed as the triple-charged form ([M#3H]3#: 784.3). The inset shows the peptide
sequence and the observed y and b ion fragments. The modified cysteine is indicated in red.
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DHPPA Inhibits TR! Binding to the NR Corepressor
Coactivators and corepressors bind to an overlapping
TR surface that comprises most of the H3–H5 region of
the AF-2 surface (15, 24) but differ in their requirements
for H12. DHPPA and HPPE inhibited TR" coactivator
binding via a mechanism that involves attachment to
AF-2 and modification of Cys298; thus, we examined the
effects of DHPPA on corepressor binding.
Results from our pull-down assays suggested that DH-
PPA inhibits NR corepressor (N-CoR) binding via a mech-
anism that is similar to its effects on coactivator binding.
DHPPA inhibited interactions betweenwild-type TR" alone
(i.e. uncoupled from its ligand) and N-CoR. The C298R
mutation did not inhibit corepressor binding but rendered
the receptor insensitive to DHPPA, whereas the C309A
mutation had noobvious effect onDHPPAaction (Fig. 6). In
addition, a mutation at residue 451 (451X) that truncated
H12andpermitted strong corepressor bindingby exposing
the complete N-CoR binding surface (24) did not affect the
sensitivity of TR" to DHPPA (Fig. 6). Thus, DHPPA inhibits
TR" interactions with corepressors via a mechanism that
requires Cys298 but is independent of H12.
DISCUSSION
In this paper, we report the x-ray structure of TR" in
complex with our prototype SID, DHPPA, at 2.3-Å
resolution. In addition, results of our mass spectro-
scopic and mutational analyses reveal that the primary
target of DHPPA is a specific cysteine residue
(Cys298). These combined structural and functional
data also indicate that DHPPA is a prodrug that pro-
duces the active compound HPPE by "-elimination,
and HPPE specifically targets cysteines in the binding
interface. The resulting covalent complex is then un-
able to recruit coregulators.
Our x-ray structure of TR" in complex with HPPE
confirms that our lead compound interacts specifically
with AF-2. We observed a single HPPE molecule that
binds to the TR" AF-2 surface with 1:1 stoichiometry,
and there is no evidence that the compound binds
elsewhere. The structure also confirms our prediction
that DHPPA liberates a reactive intermediate (HPPE)
that is in contact with the TR" surface. Although we
incubated TR"-Triac crystals with the parental "-ami-
no-ketone DHPPA, the !,"-unsaturated ketone HPPE
bound to the TR" AF-2 pocket. Nevertheless, we did
not detect electron density that would be consistent
with a covalent bond forming between the unsaturated
part of HPPE and nearby cysteine residues. Finally,
biochemical experiments indicated that little, if any,
HPPE escapes into solution. Thus, our structure prob-
ably represents a reaction intermediate in which the
active form of the compound interacts with TR" but
has not yet completed reaction with the receptor
surface.
Functional analysis indicates that the major target
for HPPE modification is Cys298, which lies close to
the AF-2 cleft. Mass spectroscopic analysis reveals
that this residue is modified by HPPE at stoichiometric
levels in solution. Moreover, Cys298 mutations
uniquely render TR" insensitive to DHPPA and HPPE
action, as revealed by inhibition of TR" interactions
with SRC2 and N-CoR in pull-down assays. Although
we mostly detect modification at Cys298, HPPE is not
Fig. 5. Mutation at Cys298 But Not at Cys309 Uniquely
Abolishes DHPPA Action
Two SDS-PAGE gels showing quantities of in vitro-trans-
lated T3-liganded wild-type (WT) TR" or mutant TRs retained
in pull-down assays using bacterially expressed GST-SRC2
(amino acids 563-1121) at 3 #g per assay in the presence of
increasing concentrations (micromolar) of DHPPA.
Fig. 6. DHPPA Inhibits Corepressor N-CoR Binding to TR"
SDS-PAGE gel showing quantities of in vitro-translated,
unliganded wild-type (WT) TR" or mutant TRs retained on
GST-N-CoR (amino acids 1944–2453) in pull-down assays in
the presence of increasing concentrations (micromolar) of
DHPPA.
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completely specific; there are low levels of modifica-
tion at Lys211 and Cys388. In addition, we were not
able to detect tryptic peptides that overlap Cys309 by
mass spectroscopic analysis, so we are not yet able to
rule out the possibility that HPPE reacts with this res-
idue at low levels. Nevertheless, Cys309 mutations do
not affect DHPPA and HPPE action, suggesting that
this residue is not an important target for these SIDs.
Supporting a specific molecular mode of action, none
of these residues is highly reactive with nonspecific
electrophiles.
Together, our findings suggest a likely mechanism
for DHPPA action. We postulate that the time depen-
dency of the reaction and the loss of diffraction in the
crystal are indicative of a two-step binding mode. The
first step is reversible binding of HPPE in the AF-2
pocket, with orientation of the unsaturated part of the
ketone toward the nearby nucleophilic side chain of
Cys298. After effective positioning, the second step, a
slow interconversion of this complex to the covalent
adduct, alters the structure sufficiently to prevent for-
mation of diffracting crystals. Because Cys298 is dis-
pensable for coactivator binding to TR" per se but is
absolutely required for HPPE action, the formation of
the Cys298/HPPE adduct most likely interferes in a
steric manner with coactivator binding to the AF-2
cleft. Prolonged soaking destroys the crystals; there-
fore, we believe that other residues, probably those
identified by mass spectrometry, are sufficiently reac-
tive to be alkylated and damage lattice associations.
Some aspects of the reaction mechanism remain
unclear. First, we do not know whether the conversion
of DHPPA to HPPE occurs in solution with subsequent
binding to TR" AF-2, or whether it takes place at the
AF-2 surface. Mannich base elimination occurs slowly
in solution and rapidly at protein surfaces; therefore,
we favor the latter possibility. This is bolstered by the
fact that we do not detect the expected external prod-
ucts of reaction between buffer components and
HPPE. When bound in the mode shown in our struc-
ture, the ketone carbonyl oxygen is 5.5 Å from Glu457,
and the ketone !-carbon is 5.7 Å from Lys306. This
structure raises the possibility that these charged res-
idues facilitate the "-elimination reaction. If so, then
the nature of the TR" active site may play an important
role in reactivity of the compound. Second, it is not
obvious why Cys298 is the preferred target for modi-
fication. There are four possible target cysteine resi-
dues near AF-2. Our structure reveals that the reactive
group of HPPE is not positioned appropriately to mod-
ify Cys294 and that Cys308 is buried in the core of the
receptor. Furthermore, Cys309 lies at the base of AF-2
close to HPPE’s unsaturated ketone group. It is not
clear why this residue is not important for HPPE ac-
tion. Perhaps dynamic structural alterations that affect
the organization of the AF-2 cleft and are apparent in
comparisons of TR! and TR" structures (21) render
the Cys309 side chain inaccessible for HPPE modifi-
cation in solution.
We expect that our results will facilitate the devel-
opment of improved second-generation SIDs for TRs.
Although DHPPA and HPPE are relatively specific in-
hibitors of TR", they are not potent enough to be
useful TR antagonists in the therapeutic setting. Our
structural and functional analyses reveal important
features of the TR surface that are needed for HPPE
binding and action. The TR" AF-2 pocket contains a
narrow hydrophobic passageway that leads to a de-
fined subpocket featuring Cys309 at its bottom,
charge beacons provided by Glu457 and Lys306 at its
rim, and a flatter subsite surrounded by Cys298 and
Lys288. HPPE exploits these topological features to
bind TR". The compound is captured by the con-
certed binding of the alkyl chain into the hydrophobic
passageway and the aromatic enone moiety into the
deep concave hole; the compound targets Cys298,
which flanks the flatter hydrophobic subsite. Further-
more, mutational analysis reveals an important but
undefined role for Lys306 in DHPPA action; these
include possibly orienting the molecule in the appro-
priate manner for cysteine modification or facilitating
elimination of the parental compound, DHPPA. Fur-
thermore, our analysis also suggests ways to improve
HPPE binding. Interactions with the flatter AF-2 sub-
site that is surrounded by Cys298 and Lys288 appear
to be suboptimal, and the compound does not bind at
all to a large part of the coactivator-binding surface
bridged by Glu285. In addition, the fact that DHPPA
inhibits TR"/N-CoR interactions in a manner that is
independent of H12 implies that this helix must be
dispensable for DHPPA and HPPE action. Thus,
chemical modifications that preserve hydrophobic and
polar interactions revealed in our structure while si-
multaneously enhancing suboptimal interactions of
HPPE with unoccupied regions of the AF-2 surface
and H12 should increase the affinity of DHPPA for TR"
and improve its specificity.
Because it was possible to identify at least one SID
that binds specifically to the TR" AF-2 surface, we
expect that we will identify similar inhibitors that bind
to the AF-2 of other NRs or perhaps to alternate hy-
drophobic interaction surfaces such as dimer sites.
Given the likely complexity and dynamic nature of
such protein-interaction surfaces, we do not think that
it will be easy to identify these compounds with stan-
dard computer-based molecular modeling ap-
proaches. Instead, we suggest that high-throughput
screening approaches will identify useful leads and
that a combination of x-ray structural analysis and
further chemical modification will yield SIDs with high
specificity for NRs. Given the mechanism of action of
HPPE outlined here, we suggest that NRs with adven-
titiously placed cysteine residues in close proximity to
protein-interaction surfaces would be useful targets.
In summary, few molecules are known to interrupt
protein-protein interactions, and of those, the struc-
tures of only a few have been characterized. This study
presents the first crystal structure of a small molecule
that binds to an NR AF-2 pocket, inhibits transcription
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through its interactions at the AF-2 pocket, and pro-
vides important guidelines for future development of
improved versions of such compounds. Molecules
such as DHPPA and HPPE are the first members of a
new class of NR antagonists that are active in the
presence of hormone and will provide new options for
manipulating the actions of these receptors.
MATERIALS AND METHODS
Protein Expression and Purification
The human (h)TR" (D355R) LBD (His6 E209-D461) cDNA se-
quenceswere cloned into the BamHI and HindIII restriction sites
downstream of the hexahistidine tag of the expression vector
pETDuet-1 (Novagen, Madison, WI). The replacement of
Asp355 for arginine in the hTR" LBD construct was performed
with the QuikChange XL Site-Directed Mutagenesis kit (Strat-
agene, La Jolla, CA). The sequence was verified by DNA se-
quencing (Elim Biopharmaceuticals, Inc., Hayward, CA).
The hTR" (D355R) LBD was expressed in BL21(DE3) cells
added at OD600% 0.6). When the OD600 reached 4, cells were
harvested, resuspended in 20 ml buffer per 1 liter culture
medium (20 mM Tris; 300 mM NaCl; 0.025% Tween 20; 0.10
mM phenylmethylsulfonylfluoride; 10 mg of lysozyme, pH 7.5)
incubated for 30 min on ice, and then sonicated three times
for 3 min on ice. The lysed cells were centrifuged at
100,000 & g for 1 h, and the supernatant was loaded onto
Talon resin (20 ml; CLONTECH Laboratories, Inc., Mountain
View, CA). Protein was eluted with 500 mM imidazole (3 & 5
ml) plus ligand [3,3!,5-triiodo-L-thyronine (Sigma, St. Louis,
MO)]. Protein purity ('90%) was assessed by SDS-PAGE
and size-exclusion chromatography (FPLC), and protein con-
centration was measured by the Bradford protein assay. The
protein was dialyzed overnight against assay buffer (3 & 4
liters, 50 mM sodium phosphate; 150 mM NaCl, pH 7.2; 1 mM
dithiothreitol; 1 mM EDTA; 0.01% Nonidet P-40; and 10%
glycerol).
Crystallization, Structure Determination, and Refinement
A pregrown TR" LBD crystal was soaked with 3 #l of a 10 mM
DHPPA compound solution in dimethylsulfoxide for 1 h. The
crystal was obtained by vapor-diffusion methods (hanging-
drop technique) in 25% ethylene glycol. The protein solution
(1 #l) was mixed with 1 #l of the reservoir solution and
concentrated against 300 #l of the reservoir. The crystal was
flash cooled using liquid nitrogen and measured using the
synchrotron radiation at the 8.3.1 beam line at the Advanced
Light Source (University of California, Berkeley), where a
complete dataset was collected at 2.3-Å resolution.
The crystal belongs to space group P21 and contains two
molecules per asymmetric unit. The diffraction data were
integrated and scaled using the computer program ELVES
(University of California Berkeley) (35). Molecular-replace-
ment solution for the TR" LBD structure was obtained using
rotation and translation functions from Crystallography and
Nuclear Magnetic Resonance Systems (CNS) (36). The first
electron maps calculated after the rigid body refinement that
followed the molecular replacement displayed clear electron
density for the compound and less-defined density indicating
flexibility for its alkyl chain. During the improvement of the
protein model, the Fourier maps revealed perfectly traceable
electron density for the entire compound. A composite-omit
map that did not include the compound was calculated dur-
ing refinement for overcoming phase bias. This map was
calculated by omitting 5% of the total model, thereby allow-
ing a better tracing of the main alkyl chain in the compound.
Model building was done using QUANTA software (Accelrys
Software, San Diego, CA), which was monitored using the
R-free factor.
Calculation of the electron density maps and crystallo-
graphic refinement was performed with CNS software using
the target parameters of Engh and Huber (37). Several cycles
of model building, conjugate gradient minimization, and sim-
ulated annealing using CNS resulted in structures with good
stereochemistry. A Ramachandran plot showed that most of
the residues fall into the most favored or allowed regions. The
statistics for data collection and refinement are presented in
Table 1. The structure has been deposited with the Protein
Data Bank (PDB) and assigned the following ID number: PDB
ID 2F9E, RCSB ID RCSB035615.
Pregrown TR" crystals soaked with the same 10 mM HPPE
compound solution in dimethylsulfoxide for longer than 1 h
failed to diffract beyond 10-Å resolution at Advanced Light
Source.
Tandem Mass Spectrometric Analysis
TR" sample in buffer (3 & 4 liters, 50 mM sodium phosphate;
150 mM NaCl, pH 7.2; 1 mM dithiothreitol; 1 mM EDTA; 0.01%
Nonidet P-40; and 10% glycerol) was denatured by addition
of 8 M urea, diluted to 1 M urea, and then digested overnight
by addition of trypsin at 1:50 ratio by mass. The resulting
peptides were subjected to nanoscale liquid chromatogra-
phy/mass spectrometry analysis using a QTrap mass spec-
trometer (Applied Biosystems/Sciex, Foster City, CA) cou-
pled to an LC Packings UltiMate on-line reverse-phase
chromatography system (Dionex, Sunnyvale, CA). Peptides
were eluted over the course of 2 h by using a gradient of
5–30% acetonitrile at a flow rate of 150 nl/min. Peptide-
fragmentation spectra were automatically acquired using the
Enhanced Product Ion scan modality. The resulting data were
analyzed using MASCOT software (Matrix Science). The soft-
ware was asked to consider possible HPPE-mediated alky-
lation of cysteine and lysine residues.
Table 1. Statistics for Data Collection and Refinement of
TR Mutant TR-D355R Crystals Soaked with the
Unsaturated Ketone HPPE
Measure Statistic
No. of molecules per asymmetric unit 2
Space group P21
Cell constants a/b/c (Å) 55.13/92.87/58.35
" 109.65
Resolution (Å) 2.3
No. of unique reflections 24,968
Completeness
Overall (%) 96.0
Outermost shell (%) 99.9
R mergea
No. of reflections used
per refinement
24,966
Resolution range (Å) 500–2.29
R factorb (%) 21.6
R freec (%) 25.6
No. of water molecules 348
Matthews coefficient 2.34
Solvent content (%) 47.59
Ramachandran plot
Most favored (%) 92
Allowed (%) 7.5
a R merge % (hkl – I / (hkl I
b R factor % (hkl !Fo – Fc / (hkl Fo
c R free set contained 5% of total data
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Pull-Down Assays
TR" labeled with 35[S] methionine was produced in vitro using
the TNT-Coupled Reticulocyte Lysate System (Promega
Corp., Madison, WI). The glutathione-S-transferase (GST) fu-
sions were expressed in Escherichia coli BL21 purified, and
anchored to a solid support (agarose-glutathione beads) ac-
cording to the manufacturer’s instructions. For binding as-
says, bead suspensions containing 10 #g GST fusion protein
were incubated with 3 #l 35S-labeled wild-type or mutant TR"
in 150 #l IPAB-80 buffer containing 2 #g/ml BSA, 10–6 M T3,
and various concentrations of DHPPA, HPPE, or controls.
After incubation for 2 h at 4 C, beads were washed (three
times) with 1 ml IPAB-80 buffer and heated to 100 C for 3 min.
Bound proteins were separated by SDS-PAGE (10% poly-
acrylamide) and visualized by autoradiography and quantified
on a Kodak M1 apparatus with Molecular Imaging software.
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